DLTR earnings call for the period ending January 30, 2021.
Chinese exhibitors should stop wantonly raising movie ticket prices or else prepare to face consumer backlash, a key government-affiliated consumer rights body said in a new report. The high price of movie tickets was one of the top categories of consumer complaints over the country’s big Chinese New Year holiday, according to the China Consumers […]
Shelton, CT, March 03, 2021 (GLOBE NEWSWIRE) -- Hubbell Incorporated (NYSE: HUBB) (“Hubbell” or the “Company”) today announced that it has successfully priced an offering of $300 million aggregate principal amount of 2.300% senior notes maturing in 2031. The offering is expected to close on March 12, 2021, subject to customary closing conditions. Net proceeds from the offering, together with cash on hand, are expected to be used to redeem in full all of the Company’s outstanding 3.625% Senior Notes due 2022 in an aggregate principal amount of $300 million, which have a stated maturity date of November 15, 2022, and to pay any premium and accrued interest in respect thereof. BofA Securities, Inc., J.P. Morgan Securities LLC and HSBC Securities (USA) Inc. acted as joint book-running managers for the offering. Hubbell has filed a registration statement with the U.S. Securities and Exchange Commission (the “SEC”), including a prospectus for the offering to which this press release relates. The registration statement became effective upon filing. You should read the prospectus in that registration statement, any applicable prospectus supplement and the other documents that Hubbell has filed with the SEC for more complete information about the Company and this offering before making any investment decision. A copy of any prospectus or prospectus supplement relating to any such transaction may be obtained for free from the SEC’s website at www.sec.gov. Copies of the prospectus and the prospectus supplement can be obtained by contacting BofA Securities, Inc. at email@example.com or calling toll-free 1-800-294-1322, J.P. Morgan Securities LLC at 383 Madison Ave. New York, NY 10179, Attention: Investment Grade Syndicate Desk, 3rd Floor, or calling collect at 212-834-4533, or HSBC Securities (USA) Inc., 452 Fifth Avenue, New York, New York 10018, Attention: Transaction Management Group, or calling toll-free at 866-811-8049. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the notes described herein or any other securities, nor shall there be any sale of these notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful. About Hubbell Hubbell is an international manufacturer of high quality, reliable electrical products and utility solutions for a broad range of customer and end market applications. With 2020 revenues of $4.2 billion, Hubbell operates manufacturing facilities in the United States and around the world. The corporate headquarters is located in Shelton, CT. Forward Looking Statements This press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements about the Company’s expected capital resources, liquidity, financial performance, pension funding, and results of operations and are based on the Company’s reasonable current expectations. In addition, all statements regarding the expected financial impact of the integration of acquisitions, adoption of updated accounting standards and any expected effects of such adoption, restructuring plans and expected associated costs and benefits, intent to repurchase shares of common stock, and change in operating results, anticipated market conditions and productivity initiatives are forward looking. These statements may be identified by the use of forward-looking words or phrases such as “believe”, “expect”, “anticipate”, “intend”, “depend”, “should”, “plan”, “estimated”, “predict”, “could”, “may”, “subject to”, “continues”, “growing”, “prospective”, “forecast”, “projected”, “purport”, “might”, “if”, “contemplate”, “potential”, “pending,” “target”, “goals”, “scheduled”, “will likely be”, and similar words and phrases. Discussions of strategies, plans or intentions often contain forward-looking statements. Important factors, among others, that could cause the Company’s actual results and future actions to differ materially from those described in forward-looking statements include, but are not limited to: the scope and duration of the novel coronavirus, or COVID-19, global pandemic and its impact on global economic systems, the Company’s employees, sites, operations, customers, and supply chain; changes in demand for the Company’s products, market conditions, product quality, or product availability adversely affecting sales levels; ability to effectively develop and introduce new products; changes in markets or competition adversely affecting realization of price increases; failure to achieve projected levels of efficiencies, cost savings and cost reduction measures, including those expected as a result of the Company’s lean initiatives and strategic sourcing plans; impacts of trade tariffs, import quotas or other trade restrictions or measures taken by the U.S., U.K. and other countries, including the recent and potential changes in U.S. trade policies; failure to comply with import and export laws; availability, costs, and quantity of raw materials, purchased components, energy and freight; changes relating to impairment of the Company’s goodwill and other intangible assets; inability to access capital markets or failure to maintain the Company’s credit ratings; changes in expected or future levels of operating cash flow, indebtedness and capital spending; general economic and business conditions in particular industries, markets or geographic regions, as well as inflationary trends; regulatory issues, changes in tax laws including revisions or clarifications of the Tax Cuts and Job Act of 2017, or changes in geographic profit mix affecting tax rates and availability of tax incentives; major disruption in one or more of the Company’s manufacturing or distribution facilities or headquarters, including the impact of plant consolidations and relocations; changes in the Company’s relationships with, or the financial condition or performance of, key distributors and other customers, agents or business partners which could adversely affect the Company’s results of operations; impact of productivity improvements on lead times, quality and delivery of product; anticipated future contributions and assumptions including changes in interest rates and plan assets with respect to pensions and other retirement benefits, as well as pension withdrawal liabilities; adjustments to product warranty accruals in response to claims incurred, historical experiences and known costs; unexpected costs or charges, certain of which might be outside of the Company’s control; changes in strategy, economic conditions or other conditions outside of the Company’s control affecting anticipated future global product sourcing levels; ability to carry out future acquisitions and strategic investments in the Company’s core businesses as well as the acquisition related costs; ability to successfully execute, manage and integrate key acquisitions, mergers, and other transactions, as well as the failure to realize expected synergies and benefits anticipated when the Company makes an acquisition; the ability to effectively implement Enterprise Resource Planning systems without disrupting operational and financial processes; the ability of government customers to meet their financial obligations; political unrest in foreign countries; the impact of Brexit and other world economic and political issues; the impact of natural disasters or public health emergencies, such as the COVID-19 global pandemic, on the Company’s financial condition and results of operations; failure of information technology systems, security breaches, cyber threats, malware, phishing attacks, break-ins and similar events resulting in unauthorized disclosure of confidential information or disruptions or damage to information technology systems that could cause interruptions to the Company’s operations or adversely affect the Company’s internal control over financial reporting; incurring significant and/or unexpected costs to avoid manage, defend and litigate intellectual property matters; future repurchases of common stock under the Company’s common stock repurchase program; changes in accounting principles, interpretations, or estimates; failure to comply with any laws and regulations, including those related to data privacy and information security, environmental and conflict-free minerals; the outcome of environmental, legal and tax contingencies or costs compared to amounts provided for such contingencies, including contingencies or costs with respect to pension withdrawal liabilities; improper conduct by any of the Company’s employees, agents or business partners that damages the Company’s reputation or subjects us to civil or criminal liability; the Company’s ability to hire, retain and develop qualified personnel; adverse changes in foreign currency exchange rates and the potential use of hedging instruments to hedge the exposure to fluctuating rates of foreign currency exchange on inventory purchases; transitioning from LIBOR to a replacement alternative reference rate; and other factors described in the Company’s SEC filings, including the “Business”, “Risk Factors”, and “Quantitative and Qualitative Disclosures about Market Risk” Sections in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Any such forward-looking statements are not guarantees of future performances and actual results, developments and business decisions may differ from those contemplated by such forward-looking statements. The Company disclaims any duty to update any forward-looking statement, all of which are expressly qualified by the foregoing, other than as required by law. CONTACT: Jonathon Murphy Hubbell Incorporated 40 Waterview Drive P.O. Box 1000 Shelton, CT 06484 475-882-4000
Studio397 brand and name to remain under Motorsport Games banner Updates and iteration of rFactor 2 to continue under Studio397 MIAMI, March 03, 2021 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games”), a leading racing game developer, publisher and esports ecosystem provider of official motorsport racing series throughout the world, announced today that it has entered a binding term sheet to acquire Studio397 BV, the company behind the industry leading rFactor 2 racing simulation platform, from Luminis International BV. The acquisition will see Studio397 continue its work on rFactor 2 while also developing the physics and handling models for Motorsport Games’ forthcoming projects. Motorsport Games expects to utilize its resources and expertise to enhance the rFactor 2 offering, especially in areas highlighted by the racing community. Studio397 and Motorsport Games have long worked in tandem, with rFactor 2 providing the simulation platform for the highly successful 24 Hours of Le Mans Virtual race, as well as the Formula E Race at Home Challenge, both of which were operated by Motorsport Games. It is expected that Studio397 will retain its name and branding with the existing development team and management will remain with the studio. “We have been working with the team at Studio397 for a long time on both game development and esports. This is an acquisition that, when completed, makes complete sense for all parties and we are delighted to have them agree to join the Motorsport Games family,” said Stephen Hood, President of Motorsport Games. “Studio397 has a clear passion for virtual racing and together we recognised an opportunity to work as one team to advance the genre to the next level,” continued Hood. “We see this as great news for the sim racing community as we can now leverage the best elements of the rFactor 2 platform, combine it with our foundational use of Unreal Engine (developed by Epic Games) and layer in the additional components our talented teams have spent the last two years developing. Our aim was to start out with a product that had heart and soul. When the planned acquisition is completed, we can operate safe in the knowledge that another piece of an ambitious puzzle has been secured.” “After growing rFactor 2 in the last five years, we are excited to take the next step with Motorsport Games, advancing rFactor 2 and integrating its advanced simulation technology into future projects. We share a common ambition to be the best at what we do,” said Marcel Offermans, Managing Director, Studio397. “This planned acquisition is another clear signal of our intention to establish Motorsport Games as the leader in the virtual racing space. We continue to utilize the capital committed by our shareholders to aggressively pursue our goals,” added Dmitry Kozko, CEO of Motorsport Games. “Securing rFactor 2 and the expertise behind it will be a huge advancement for us. We will bring our experience and knowledge to help maximize the potential of the rFactor 2 platform while also having exclusive access to its best-in-class technology for our future projects.” “The level of simulation and the feeling of driving offered by rFactor 2 is second to none,” shared Fernando Alonso, Motorsport Games shareholder, Alpine Formula 1 driver and two-time Formula 1 World Drivers’ Champion. “I am delighted that Studio397 and rFactor 2 will be joining our Motorsport Games family and I am sure that we will enjoy a great deal of success together.” This latest announcement from Motorsport Games follows a string of exciting developments, including the upcoming acquisition of KartKraft from Black Delta and announcements of forthcoming games based upon the iconic 24 Hours of Le Mans and the British Touring Car Championship, in addition to the company’s existing NASCAR projects. For more information about Motorsport Games visit www.motorsportgames.com and follow our social media channels: Facebook, Twitter and LinkedIn. About Motorsport Games:Motorsport Games, a Motorsport Network company, combines innovative and engaging video games with exciting esports competitions and content for racing fans and gamers around the globe. The Company is the officially licensed video game developer and publisher for iconic motorsport racing series including NASCAR, 24 Hours of Le Mans and the British Touring Car Championship (“BTCC”). Motorsport Games is an award-winning esports partner of choice for 24 Hours of Le Mans, Formula E, BTCC, the FIA World Rallycross Championship and the eNASCAR Heat Pro League among others.For more information about Motorsport Games visit: www.motorsportgames.com About Luminis and Studio397Luminis International BV is a software and technology company with offices in the Netherlands and the United Kingdom. Our mission is to create exponential value for organizations by using software technology. With 200 colleagues we work with more than 100 customers, including major brands such as KLM, Nike and Bol.com. Luminis also develops cloud-based data solutions under the brands InformationGrid and MediGrid. In 2016 Luminis founded Studio397, aimed specifically at the professional race simulator market. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as "continue," "will," "may," "could," "should," "expect," "expected," "plans," "intend," "anticipate," "believe," "estimate," "predict," "potential," and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Motorsport Games and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to whether to Motorsport Games will be able to negotiate and enter into the definitive agreements with respect to the acquisition of Studio397 and its rFactor 2 platform, whether all conditions precedent in the definitive agreements to acquire Studio397 and its rFactor 2 platform will be satisfied, whether the closing of such acquisition will occur and whether Motorsport Games will achieve its goals. Additional examples of such risks and uncertainties include, but are not limited to (i) Motorsport Games’ ability (or inability) to maintain existing, and secure additional, licenses and contracts with the sports series; (ii) Motorsport Games’ ability to successfully manage and integrate any joint ventures, acquisitions of businesses, solutions or technologies; (iii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iv) the ability to attract and retain qualified employees and key personnel; (v) adverse effects of increased competition on Motorsport Games’ business; (vi) the risk that changes in consumer behavior could adversely affect Motorsport Games’ business; (vii) Motorsport Games’ ability to protect its intellectual property; and (viii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent registration statement on Form S-1 and current reports on Form 8-K filed by Motorsport Games with the Securities and Exchange Commission. Motorsport Games anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Motorsport Games assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Motorsport Games’ plans and expectations as of any subsequent date. Press:firstname.lastname@example.org Investors:Ashley DeSimoneAshley.Desimone@icrinc.com
FLORHAM PARK, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present at the H.C. Wainwright Global Life Sciences Conference being held from March 9-10, and at the 31st Annual Oppenheimer Healthcare Conference being held from March 16-18. Both conferences are being hosted virtually. H.C. Wainwright & Co. Global Life Sciences ConferenceDate: Presentation Available On-Demand March 9-10, 2021Registration: Click Here 31st Annual Oppenheimer Healthcare ConferenceDate: March 16, 2021 at 1:10 PM Eastern TimeRegistration: Click Here Replays of the presentations will be available online in the investor relations section of the Company’s website for 90 days following the events. About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech. Forward Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast.” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for its lead asset PDS0101; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Media & Investor Relations Contact: Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: email@example.com Jacob GoldbergerCG CapitalPhone: +1 (404) 736-3841Email: firstname.lastname@example.org
PennyMac Mortgage Investment Trust (NYSE: PMT) today announced the appointment of Doug Jones as President and Chief Mortgage Banking Officer, in conjunction with a similar announcement today by PennyMac Financial Services, Inc. (NYSE: PFSI), PMT’s manager and service provider. Mr. Jones had previously served as PMT’s Senior Managing Director and Chief Mortgage Banking Officer. In his new role, Mr. Jones continues to be responsible for all activities relating to the Company’s loan production and loan servicing businesses.
Babcock & Wilcox Enterprises, Inc. is to present at the B. Riley Securities Sustainable Energy & Technology Conference on March 10, 2021.
BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021. A live webcast of the conference call can be accessed through the “Investors” tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID #7657415. Please dial in at least 15 minutes in advance to ensure a timely connection to the call. About Flexion TherapeuticsFlexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun. Visit flexiontherapeutics.com. Contact: Scott YoungVice President, Corporate Communications & Investor RelationsT: email@example.com
tZERO CEO Saum Noursalehi and the tZERO management team will host an update and Q&A session on Wednesday, March 10, 2021, at 4pm ET.
ROCKAWAY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming investor conferences. H.C. Wainwright Global Life Sciences ConferenceFormat: pre-recorded fireside chat followed by 1x1 virtual investor meetingsDate: March 9 – 10 The fireside chat will be available for viewing beginning on Tuesday, March 9, 2021 at 7:00 a.m. ET. Following the conference a webcast replay of the presentation will be available for 90 days on the Investor section of the company’s website, www.electrocore.com M Vest LLC and Maxim Group LLC Emerging Growth Virtual ConferenceFormat: pre-recorded corporate presentation followed by 1x1 virtual investor meetingsDate: March 17 – 18 The presentation will be available for viewing beginning on Wednesday, March 17, 2021 at 9:00 a.m. ET. Investors can register for the conference HERE. About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. For more information, visit www.electrocore.com. Investors: Hans VitzthumLifeSci Advisors617firstname.lastname@example.org or Media Contact: Summer DiazelectroCore973email@example.com
Semtech Corporation (NASDAQ: SMTC), a leading supplier of high performance analog and mixed-signal semiconductors and advanced algorithms, today announced plans to release the financial results of its fourth quarter and fiscal year 2021 after the close of the market on Wednesday, March 17, 2021. The results will be released through Business Wire and posted at www.semtech.com.
RGAX today announced AURA NEXT, the SaaS-based underwriting decision management platform from Reinsurance Group of America, Incorporated (RGA) and RGAX, completed a Service Organization Control (SOC) 2 Type II examination performed by an external auditing firm.
VANCOUVER and MINNEAPOLIS, March 03, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021. A recorded presentation by Bill Little, Neovasc’s Chief Operating Officer, will be available on the Conference website starting at 7:00 am EST on March 9. Company management will also be scheduling one-on-one meetings with investors; meetings may be requested through H.C. Wainwright. A link to the recorded presentation will also be available in the investor relations section of the Neovasc website at https://www.neovasc.com/investors/. About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com. Investors Mike Cavanaugh Westwicke/ICR Phone: +1.646.877.9641 Mike.Cavanaugh@westwicke.com Media Sean Leous Westwicke/ICR Phone: +1.646.677.1839 Sean.Leous@icrinc.com Forward-Looking Statement Disclaimer Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to the expansion of its product range and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including those described in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three and nine months ended September 30, 2020 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Alignment Healthcare, a mission-based, tech-enabled Medicare Advantage company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Alignment Healthcare intends to list its common stock on the Nasdaq Global Select Market under the symbol "ALHC."
New York, New York--(Newsfile Corp. - March 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bit Digital, Inc. (NASDAQ: BTBT) between December 21, 2020 and January 8, 2021, inclusive (the "Class Period"), of the important March 22, 2021 lead plaintiff deadline.SO WHAT: If you purchased Bit Digital securities during the Class Period you may be entitled to compensation without payment of any ...
CorEnergy Infrastructure Trust, Inc. (NYSE: CORR, CORRPrA) ("CorEnergy" or the "Company") today announced financial results for the fourth quarter 2020 and fiscal year ended December 31, 2020.
Ecolab Inc. President and CEO Christophe Beck will address financial analysts virtually at the G.research Specialty Chemicals Conference on Thursday, March 11, 2021. Ecolab will offer a live webcast of Mr. Beck’s presentation. Details for the webcast are as follows:
PennyMac Financial Services, Inc. (NYSE: PFSI) today announced the appointment of Doug Jones as President and Chief Mortgage Banking Officer. Mr. Jones had previously served as the Company’s Senior Managing Director and Chief Mortgage Banking Officer, as well as President of PennyMac Loan Services, the Company’s mortgage banking subsidiary. In his new role, Mr. Jones continues to be responsible for all activities relating to the Company’s loan production and loan servicing businesses.
Arconic Corp. (NYSE: ARNC) ("Arconic" or "the Company") announced today that it closed its offering of an additional $300 million aggregate principal amount of the Company’s 6.125% Senior Secured Second-Lien Notes due 2028 (the "Additional Notes"). The Additional Notes were sold at 106.25% of par and the Company expects net proceeds of approximately $314 million.
Dallas, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- CompX International Inc. (NYSE American: CIX) announced today sales of $30.0 million for the fourth quarter of 2020 compared to $29.6 million in the same period of 2019. Operating income was $2.3 million in the fourth quarter of 2020 compared to $3.5 million in the same period of 2019. Net income was $2.3 million, or $0.17 per diluted share, for the fourth quarter of 2020 compared to $3.2 million, or $0.26 per diluted share, in the same period of 2019. Net sales for the year ended December 31, 2020 were $114.5 million compared to $124.2 million in the previous year. Operating income was $11.8 million for the year ended December 31, 2020 compared to $17.7 million for 2019. Net income for the year ended December 31, 2020 was $10.3 million, or $0.83 per diluted share, compared to $16.0 million, or $1.29 per diluted share, for the year ended December 31, 2019. Net sales increased in the fourth quarter of 2020 compared to the same period in 2019 as lower Security Products sales were more than offset by increased Marine Components sales, with the towboat market representing most of the increase in marine sales. Operating income decreased for the fourth quarter of 2020 compared to the fourth quarter of 2019 as the improvement in Marine Components operating income was offset by the decline of Security Products operating income. Security Products operating income for the period declined primarily due to the higher cost of sales noted below, as well as increased medical costs. Net sales decreased for the full year of 2020 compared to the full year of 2019 due to lower Security Products sales primarily resulting from customer disruptions caused by the COVID-19 pandemic, somewhat offset by higher Marine Components sales. Operating income for the full year of 2020 compared to the same period in 2019 was negatively impacted by higher fixed cost per unit of production as the result of lower production volumes in the second and third quarters which increased the cost of inventory produced in these quarters and sold in the second half of 2020. Additionally, operating income for the full year of 2020 compared to prior year was negatively impacted by increased employer paid medical costs unrelated to the pandemic. In the second half of 2020, our sales began to recover from the historically low levels we experienced during the second quarter, with sales steadily improving for the remainder of the year. In the second half of the year, our manufacturing operations returned to more normal production rates as demand from our customers began to return, although Security Products operations did not recover to pre-pandemic levels. The extent of the impact of the COVID-19 pandemic on our future operations will depend on the time period and degree to which the COVID-19 pandemic persists in the economy, including the timing and extent to which our customers’ operations continue to be impacted, our customers’ perception as to when consumer demand for their products will return to pre-pandemic levels and on any future disruptions in our operations or our suppliers’ operations, all of which are difficult to predict. CompX is a leading manufacturer of security products and recreational marine components. It operates from three locations in the U.S. and employs approximately 513 people. Forward-Looking Statements The statements in this press release relating to matters that are not historical facts are forward-looking statements that represent management’s belief and assumptions based on currently available information. Although CompX believes the expectations reflected in such forward-looking statements are reasonable, it cannot give any assurances that these expectations will be correct. Such statements, by their nature, involve substantial risks and uncertainties that could significantly impact expected results, and actual future results could differ materially from those predicted. While it is not possible to identify all factors, CompX continues to face many risks and uncertainties. The factors that could cause our actual future results to differ materially include, but are not limited to, the following: Future demand for our products, Changes in our raw material and other operating costs (such as zinc, brass, aluminum, steel and energy costs) and our ability to pass those costs on to our customers or offset them with reductions in other operating costs, Price and product competition from low-cost manufacturing sources (such as China), The impact of pricing and production decisions, Customer and competitor strategies including substitute products, Uncertainties associated with the development of new products and product features, Future litigation, Our ability to protect or defend our intellectual property rights,Potential difficulties in integrating future acquisitions, Decisions to sell operating assets other than in the ordinary course of business, Environmental matters (such as those requiring emission and discharge standards for existing and new facilities), The ultimate outcome of income tax audits, tax settlement initiatives or other tax matters, including future tax reform, The impact of current or future government regulations (including employee healthcare benefit related regulations), General global economic and political conditions that disrupt or introduce instability into our supply chain, impact our customers’ level of demand or our customers’ perception regarding demand or impair our ability to operate our facilities (including changes in the level of gross domestic product in various regions of the world, natural disasters, terrorist acts, global conflicts and public health crises such as COVID-19), Operating interruptions (including, but not limited to labor disputes, hazardous chemical leaks, natural disasters, fires, explosions, unscheduled or unplanned downtime, transportation interruptions, cyber-attacks and public health crises such as COVID-19); and Possible disruption of our business or increases in the cost of doing business resulting from terrorist activities or global conflicts. Should one or more of these risks materialize (or the consequences of such development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those currently forecasted or expected. CompX disclaims any intention or obligation to update or revise any forward-looking statement whether as a result of changes in information, future events or otherwise. * * * * * COMPX INTERNATIONAL INC.SUMMARY CONSOLIDATED STATEMENTS OF INCOME(In millions, except per share amounts) Three months ended Year ended December 31, December 31, 2019 2020 2019 2020 (Unaudited) Net sales$29.6 $30.0 $124.2 $114.5 Cost of sales 20.7 22.3 85.2 81.7 Gross margin 8.9 7.7 39.0 32.8 Selling, general and administrative expense 5.4 5.4 21.3 21.0 Operating income 3.5 2.3 17.7 11.8 Interest income 0.7 0.4 3.2 1.7 Income before taxes 4.2 2.7 20.9 13.5 Provision for income taxes 1.0 0.4 4.9 3.2 Net income$3.2 $2.3 $16.0 $10.3 Basic and diluted net income per common share$0.26 $0.17 $1.29 $0.83 Weighted average diluted common shares outstanding 12.4 12.5 12.4 12.4 CONTACT: SOURCE: CompX International Inc. CONTACT: Janet G. Keckeisen, Investor Relations, 972.233.1700